|Bid||2,958.00 x 0|
|Ask||2,958.00 x 0|
|Day's Range||2,884.00 - 2,980.00|
|52 Week Range||2,014.00 - 3,234.00|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||70.36|
|Earnings Date||Nov. 22, 2021|
|Forward Dividend & Yield||0.42 (1.46%)|
|Ex-Dividend Date||May 27, 2021|
|1y Target Est||2,968.00|
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comVANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) -- NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased